Herantis Pharma Plc · OMXHEX:HRTIS

Herantis Pharma — FY2023 Earnings Presentation

17 slides from Herantis Pharma's earnings presentation, Mar 6, 2024

1. Slide 1: FY 2023 presentation

   FY 2023 presentation March 6, 2024 www.herantis.com © 2014-2023 HERANTIS PHARMA Plc. All rights reserved.

2. Slide 2: Forward-looking Statement

   Forward-looking Statement This company presentation includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis’ future financial position and results of

3. Slide 3: Herantis in Brief

   Herantis in Brief Herantis Pharma plc was founded in Helsinki, Finland in 2008; Listed at Nasdaq First North Helsinki Developing disease-modifying treatment to address the unmet clinical need in Parkinson’s disease and other neurodegenerative diseases Lead asset HER-096 is a small engineered peptide

4. Slide 4: Normal function of the dopaminergic neurons

   Normal function of the dopaminergic neurons INACTIVATED ER* MICROGLIAL Nucleus CELLS FUNCTIONAL DOPAMINERGIC NEURON (pre-synaptic / transmittor) NEURON *ER = endoplastic reticulum (post-synaptic / receiver) MOTOR FUNCTION www.herantis.com © 2014-2023 HERANTIS PHARMA Plc. All rights reserved. 4

5. Slide 5: Parkinson's disease: dopaminergic neurons degenerate in mid-brain

   Parkinson’s disease: dopaminergic neurons degenerate in mid-brain (sustantia nigra) 1. CHRONIC NEURONAL ENDOPLASTIC ACTIVATED MICROGLIAL RETICULUM (ER) STRESS CELLS • Caused by accumulation of misfolded proteins in the ER 2. Accumulation of Endoplastic • Chronic activation of Unfolded toxic ⍺-synucl

6. Slide 6: Preclinical data: HER-096 acts on the key mechanisms of Parkinson's disease

   Preclinical data: HER-096 acts on the key mechanisms of Parkinson’s disease 1. NORMALIZATION OF THE ER FUNCTION • HER-096 target is Unfolded Protein Response (UPR) Pathway 2. Decreased ⍺- • HER-096 binds to the UPR regulatory molecule synuclein aggregates (GRP-78 / BiP) and inactivate UPR INACTIVATE

7. Slide 7: HER-096 restores the normal function of the dopaminergic neurons

   HER-096 restores the normal function of the dopaminergic neurons DEGENERATING DOPAMINERGIC NEURON FUNCTIONAL DOPAMINERGIC NEURON (pre-synaptic / transmittor) (pre-synaptic / transmittor) ACTIVATED MICROGLIAL CELLS INACTIVATED MICROGLIAL CELLS HER-096 NEURON NEURON (post-synaptic / receiver) (post-sy

8. Slide 8: Status of HER-096 Program

   Status of HER-096 Program • Manufacturing Ø HER-096 bulk manufactured by solid phase peptide synthesis, current scale 1000 grams, straightforward further scale-up Ø Phase 1b GMP manufacturing ongoing Ø Formulation development work on-going to decrease the volume of injection • Preclinical toxicology

9. Slide 9: Business highlights 2023

   Business highlights 2023 • HER-096 Phase 1a clinical trial met all primary and secondary endpoints ØIn October, the read-out from the clinical trial demonstrated favorable safety and tolerability profile, fast uptake of HER-096, and significant HER-096 concentration in the cerebrospinal fluid (CSF)

10. Slide 10: Events after the reporting period

    Events after the reporting period • March 4th, Herantis announced two poster presentations at the AD/PD 2024 conference. ØPhase 1a first-in-human trial results of HER-096 to be presented to the scientific audience for the first time. ØPreclinical data shows that HER-096 promotes functional recovery

11. Slide 11: Net profit for the year of 2023 due to cost savings and extraordinary items

    Net profit for the year of 2023 due to cost savings and extraordinary items Other operating income (EUR thousands) OPEX by item (EUR thousands) Profit/Loss (EUR thousands) 2000 6000 2023 2022 5 306 280 5000 0 Total operating expenses 2023 2022 4000 -2000 Other operating 3000 expenses -4000 2000 Depr

12. Slide 12: Herantis's equity position strengthening during 2023

    Herantis’s equity position strengthening during 2023 Cash position (EUR thousands) Cash flow from operating activities Equity (EUR thousands) (EUR thousands) 6000 5 503 0 5000 4 726 5 036 2023 2022 5000 -1000 -2000 4000 4000 -3000 3000 -4000 3000 -5000 - 4 636 2000 2000 -6000 -7000 1000 1000 -8000 -

13. Slide 13: 2024 milestones for HER-096

    2024 milestones for HER-096 Phase 1b clinical trial application submitted (targeted 1H/2024) Phase 1b clinical trial application approved (targeted 2H/2024) First Parkinson’s patient dosed with HER-096 in a Phase 1b trial (targeted 2H/2024) www.herantis.com © 2014-2023 HERANTIS PHARMA Plc. All right

14. Slide 14: Seeking a partner for HER-096 to co-develop future potential

    Seeking a partner for HER-096 to co-develop future potential Significant opportunities in further development in Parkinson’s and in other neurodegenerative diseases Preclinical evidence of disease modifying HER-096 global effect patenting HER-096 is delivered to the Straightforward manufacturing hum

15. Slide 15: Herantis as an investment

    Herantis as an investment Market Problem Rapidly growing global Available treatments for Parkinson’s disease Parkinson’s disease do treatment market. Will not cure the disease or reach USD 12 billion by even slow down its 2030. progression. Evidence Disease-modifying effect Our unique solution in mo

16. Slide 16: Summary

    Summary What we want to achieve To develop a treatment to slow or stop the progression of with HER-096? Parkinson’s disease with symptomatic relief • Therapeutic concentration of HER-096 in the central nervous Evidence of subcutaneous system in humans HER-096 • Good safety and tolerability profile i

17. Slide 17: Thank you!

    Thank you! Contact details: CEO Antti Vuolanto, [email protected] CFO Tone Kvåle, [email protected] www.herantis.com © 2014-2024 HERANTIS PHARMA Plc. All rights reserved.17

Herantis Pharma — FY2023 Earnings Presentation on 6ix